Literature DB >> 8406390

Expression of CD30 and nerve growth factor-receptor in neoplastic and reactive vascular lesions: an immunohistochemical study.

P Rudolph1, T Lappe, D Schmidt.   

Abstract

A total of 118 biopsies from 20 different types of benign, malignant and reactive vascular proliferations were examined for the expression of the CD30 antigen using the monoclonal antibodies BerH2 and HRS4 on paraffin-embedded sections. The results were compared with those obtained using an antibody directed against the partially homologous nerve growth factor-receptor. The vascular character of the lesions was assessed by means of endothelial markers and the expression of intermediate filaments was verified immunohistochemically. CD30 was expressed in the endothelial component of more than the half of all tumours, with the exceptions of Kaposi's sarcoma and teleangiectatic granuloma. There was a slightly higher rate of Ki-1 positivity in malignant lesions. Nerve growth factor-receptor could be demonstrated in a similar percentage in both endothelium and pericytes, but no correlation with CD30 could be established. We conclude, therefore, that these antigens are not adequate for the differential diagnosis of vascular lesions, nor do they help distinguish between benign and malignant lesions. Their expression seems to reflect different states of cellular function or activation. It does not necessarily occur simultaneously or in the same cell type.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406390     DOI: 10.1111/j.1365-2559.1993.tb00476.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

1.  CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases.

Authors:  Meghna Alimchandani; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 May-Jun

2.  CD30 and Epstein-Barr virus RNA expression in sclerosing angiomatoid nodular transformation of spleen.

Authors:  Ilan Weinreb; Denis Bailey; Donna Battaglia; Meagan Kennedy; Bayardo Perez-Ordoñez
Journal:  Virchows Arch       Date:  2007-05-10       Impact factor: 4.064

3.  Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.

Authors:  Meili Zhang; Zhengsheng Yao; Hiral Patel; Kayhan Garmestani; Zhuo Zhang; Vladimir S Talanov; Paul S Plascjak; Carolyn K Goldman; John E Janik; Martin W Brechbiel; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-08       Impact factor: 11.205

4.  Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.

Authors:  Meili Zhang; Zhengsheng Yao; Zhuo Zhang; Kayhan Garmestani; Carolyn K Goldman; Jeffrey V Ravetch; John Janik; Martin W Brechbiel; Thomas A Waldmann
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

5.  Lymphocyte deficiency limits Epstein-Barr virus latent membrane protein 1 induced chronic inflammation and carcinogenic pathology in vivo.

Authors:  Adele Hannigan; Asif M Qureshi; Colin Nixon; Penelope M Tsimbouri; Sarah Jones; Adrian W Philbey; Joanna B Wilson
Journal:  Mol Cancer       Date:  2011-02-03       Impact factor: 27.401

6.  Ber-H2 (CD30) immunohistochemical staining of human fetal tissues.

Authors:  D Tamiolakis; N Papadopoulos; M Lambropoulou; J Venizelos; D Verettas; P Tsikouras; G Koutsougeras; H Papadopoulos; A Karpouzis; C Kouskoukis
Journal:  Int J Biol Sci       Date:  2005-10-01       Impact factor: 6.580

7.  Human embryonal epithelial cells of the developing small intestinal crypts can express the Hodgkin-cell associated antigen Ki-1 (CD30) in spontaneous abortions during the first trimester of gestation.

Authors:  Demetrio Tamiolakis; John Venizelos; Maria Lambropoulou; Silva Nikolaidou; Sophia Bolioti; Maria Tsiapali; Dionysios Verettas; Panagiotis Tsikouras; Athanasios Chatzimichail; Nikolas Papadopoulos
Journal:  Theor Biol Med Model       Date:  2005-01-11       Impact factor: 2.432

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.